|

chidamide, regorafenib, and iparomlimab/tuvonralimab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Changzheng Hospital1

Indications

  • pMMR/MSS Advanced Colorectal Cancer1
  • Advanced Colorectal Cancer in the Third-line Treatment and Beyond1
  • Cancer1

Other1 trial

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.